130 related articles for article (PubMed ID: 6208291)
21. Synergism among BIOLF-62, phosphonoformate, and other antiherpetic compounds.
Smith KO; Galloway KS; Ogilvie KK; Cheriyan UO
Antimicrob Agents Chemother; 1982 Dec; 22(6):1026-30. PubMed ID: 6297382
[TBL] [Abstract][Full Text] [Related]
22. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency.
Halford WP; Schaffer PA
J Virol; 2001 Apr; 75(7):3240-9. PubMed ID: 11238850
[TBL] [Abstract][Full Text] [Related]
23. Secondary herpes simplex virus latent infection in transplanted ganglia.
Tenser RB; Edris WA; Gaydos A; Hay KA
J Virol; 1994 Nov; 68(11):7212-20. PubMed ID: 7933103
[TBL] [Abstract][Full Text] [Related]
24. In vitro effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 5'-amino-5-iodo-2',5'-dideoxyuridine and 2-deoxy-D-glucose on latent ganglionic herpes simplex virus infection.
Pavan-Langston D; Park NH; De Clercq E
Antiviral Res; 1984 Apr; 4(1-2):53-61. PubMed ID: 6331305
[TBL] [Abstract][Full Text] [Related]
25. Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection.
Spivack JG; Fraser NW
J Virol; 1988 May; 62(5):1479-85. PubMed ID: 2833602
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of herpes simplex virus reactivation by dipyridamole in a mouse model.
Hay KA; Gaydos A; Tenser RB
J Med Virol; 1996 Oct; 50(2):198-203. PubMed ID: 8915888
[TBL] [Abstract][Full Text] [Related]
27. Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir.
Reefschläger J; Wutzler P; Thiel KD; Herrmann G
Antiviral Res; 1986 Mar; 6(2):83-93. PubMed ID: 3010858
[TBL] [Abstract][Full Text] [Related]
28. Enhanced in vitro reactivation of herpes simplex virus type 2 from latently infected guinea-pig neural tissues by 5-azacytidine.
Stephanopoulos DE; Kappes JC; Bernstein DI
J Gen Virol; 1988 May; 69 ( Pt 5)():1079-83. PubMed ID: 2453606
[TBL] [Abstract][Full Text] [Related]
29. 5-Methoxymethyldeoxyuridine-resistant mutants of herpes simplex virus type 1.
Veerisetty V; Gentry GA
Virology; 1981 Oct; 114(2):576-9. PubMed ID: 6270889
[No Abstract] [Full Text] [Related]
30. Expression of extremely low levels of thymidine kinase from an acyclovir-resistant herpes simplex virus mutant supports reactivation from latently infected mouse trigeminal ganglia.
Besecker MI; Furness CL; Coen DM; Griffiths A
J Virol; 2007 Aug; 81(15):8356-60. PubMed ID: 17522225
[TBL] [Abstract][Full Text] [Related]
31. Low-level expression and reversion both contribute to reactivation of herpes simplex virus drug-resistant mutants with mutations on homopolymeric sequences in thymidine kinase.
Griffiths A; Link MA; Furness CL; Coen DM
J Virol; 2006 Jul; 80(13):6568-74. PubMed ID: 16775343
[TBL] [Abstract][Full Text] [Related]
32. Effects of topical applications of phosphonoacetate on colonization of mouse trigeminal ganglia with herpes simplex virus type 1.
Klein RJ; Friedman-Kien AE; Kaley L; Brady E
Antimicrob Agents Chemother; 1984 Jul; 26(1):65-8. PubMed ID: 6089655
[TBL] [Abstract][Full Text] [Related]
33. Inhibition by indomethacin of in vitro reactivation of latent herpes simplex virus type 1 in murine trigeminal ganglia.
Kurane I; Tsuchiya Y; Sekizawa T; Kumagai K
J Gen Virol; 1984 Oct; 65 ( Pt 10)():1665-74. PubMed ID: 6092519
[TBL] [Abstract][Full Text] [Related]
34. Quantitative analysis of herpes simplex virus reactivation in vivo demonstrates that reactivation in the nervous system is not inhibited at early times postinoculation.
Sawtell NM
J Virol; 2003 Apr; 77(7):4127-38. PubMed ID: 12634371
[TBL] [Abstract][Full Text] [Related]
35. Isolation of bromovinyldeoxyuridine-resistant strains of herpes simplex virus and successful chemotherapy of mice infected with one such strain by using acyclovir.
Field HJ; Neden J
Antiviral Res; 1982 Oct; 2(5):243-54. PubMed ID: 6295272
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility of varicella-zoster virus to thymidine analogues.
Machida H
Biken J; 1986 Mar; 29(1):1-6. PubMed ID: 3022708
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Herpes Simplex Virus Reactivation in Explant Reveals a Method-Dependent Difference in Measured Timing of Reactivation.
Doll JR; Sawtell NM
J Virol; 2017 Aug; 91(16):. PubMed ID: 28637763
[TBL] [Abstract][Full Text] [Related]
38. Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2.
Schinazi RF; Fox JJ; Watanabe KA; Nahmias AJ
Antimicrob Agents Chemother; 1986 Jan; 29(1):77-84. PubMed ID: 3015003
[TBL] [Abstract][Full Text] [Related]
39. Acyclovir blocks cytokine gene expression in trigeminal ganglia latently infected with herpes simplex virus type 1.
Halford WP; Gebhardt BM; Carr DJ
Virology; 1997 Nov; 238(1):53-63. PubMed ID: 9375008
[TBL] [Abstract][Full Text] [Related]
40. Novobiocin and coumermycin A1 inhibit viral replication and the reactivation of herpes simplex virus type 1 from the trigeminal ganglia of latently infected mice.
Spivack JG; O'Boyle DR; Fraser NW
J Virol; 1987 Oct; 61(10):3288-91. PubMed ID: 3041048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
